Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A288466-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $112.90 | |
A288466-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $176.90 | |
A288466-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $352.90 | |
A288466-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $565.90 | |
A288466-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $919.90 |
Biased allosteric modulator of calcium-sensing receptor (CaSR)
Synonyms | AC-265347|1253901-26-6|AC265347|1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol|AC 265347|1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethan-1-ol|MLS006010713|GTPL3947|CHEMBL1256367|SCHEMBL19462840|AKOS027324495|NCGC00344509-01|SMR004701681|HY- |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | CaSR biased allosteric modulator (pEC50= 7.8-8.1). Calcimimetic. Displays ability to bias signalling towards the accumulation of pERK1/2 and IP1. Reduces parathyroid hormone (PTH) levels in rat serum without inducing the release of calcitonin. Exhibits no |
Storage Temp | Store at 2-8°C,Protected from light |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | ALLOSTERIC MODULATOR |
Mechanism of action | Allosteric modulator of CaS receptor |
Product Description | Biased allosteric modulator of calcium-sensing receptor (CaSR) Application: AC 265347 is a CaSR biased allosteric modulator (pEC50 = 7.8-8.1). Calcimimetic. Displays ability to bias signalling towards the accumulation of pERK1/2 and IP1. Reduces parathyroid hormone (PTH) levels in rat serum without inducing the release of calcitonin. Exhibits no significant activation of human GABAB or type I PTH receptors. Orally active. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol |
---|---|
INCHI | InChI=1S/C17H17NOS/c1-11-8-9-13(12(2)10-11)17(3,19)16-18-14-6-4-5-7-15(14)20-16/h4-10,19H,1-3H3 |
InChi Key | IGSZVEPQZANNAB-UHFFFAOYSA-N |
Canonical SMILES | CC1=CC(=C(C=C1)C(C)(C2=NC3=CC=CC=C3S2)O)C |
Isomeric SMILES | CC1=CC(=C(C=C1)C(C)(C2=NC3=CC=CC=C3S2)O)C |
Alternate CAS | 1253901-26-6 |
PubChem CID | 52943938 |
MeSH Entry Terms | 1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol;AC265347 |
Molecular Weight | 283.39 |
Enter Lot Number to search for COA:
Solubility | Solvent:DMSO, Max Conc. mg/mL: 28.34, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 28.34, Max Conc. mM: 100 |
---|---|
Sensitivity | Light sensitive |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H319:Causes serious eye irritation |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. |